Bartonella Inhibitory Factor for Endothelial Cell Growth

内皮细胞生长的巴尔通体抑制因子

• 批准号: 6503171
• 负责人: Michael F Minnick
• 金额: $ 14万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6503171
• 关键词: Rickettsiales; Rickettsiales disease; angiogenesis inhibitors; bacterial proteins; chick embryo; emerging infectious disease; gene deletion mutation; genetic mapping; host organism interaction; inhibitor /antagonist; laboratory rat; molecular cloning; nucleic acid sequence; protein structure function; receptor; receptor binding; vascular endothelium

DESCRIPTION (provided by applicant): Five species of Bartonella are emerging agents of infectious human disease. Because of their ability to parasitize erythrocytes and endothelial cells within the circulatory system, bartonelloses present with a wide array of cardiovascular manifestations including endocarditis, bacillary angiomatosis, peliosis, chronic bacteremia, and hemolytic anemia. Bartonella's parasitism of microvascular endothelial cells is characterized by a proliferative response triggered by a bacterial protein that we have termed Bartonella angiogenic protein (BAP). The resulting angiogenesis generates a pseudoneoplastic vascular lesion. In our work on BAP, we recently discovered an inhibitory protein from Bartonella henselae that significantly reduces the growth of human vascular endothelial cells, termed BIF. Production of BAP and BIF by Bartonella suggests that the pathogen plays an active role in regulating the growth of its host cell. However, neither the molecular nature nor mechanism of BAP or BIF are known. Therefore, the long-term goals of this project are to characterize BIF and its mechanism of action, using Bartonella henselae as a model for the genus. Specific goals to achieve these objectives will: 1) Characterize BIF at the molecular level using biochemical and molecular biological techniques, 2) Analyze BIF's mechanism by mapping domains necessary to its inhibitory activity by creating overlapping BAP deletion mutants and assaying their ability to inhibit vascular endothelial cell growth, 3) Examine BIF and BAP for antagonism in vitro and assess the angiostatic activity of BIF in vivo, and 4) initiate studies to elucidate BIF's mechanism by identifying and characterizing its cognate endothelial cell receptor(s). These experiments will generate valuable data on the molecular nature of a novel bacterial protein that can modulate the growth of human vascular endothelial cells and will help elucidate the mechanism whereby angiomatic and pseudoneoplastic disease manifestations of bartonellosis are generated during infection.

描述（由申请人提供）：五种巴尔通体是人类传染病的新发病原体。由于它们寄生于循环系统内的红细胞和内皮细胞的能力，巴顿耐菌具有广泛的心血管表现，包括心内膜炎、细菌性血管瘤病、盆腔增生、慢性菌血症和溶血性贫血。巴尔通体寄生于微血管内皮细胞的特点是由一种细菌蛋白引发的增殖反应，我们称之为巴尔通体血管生成蛋白（BAP）。由此产生的血管新生形成假性肿瘤血管病变。在我们对BAP的研究中，我们最近从亨塞巴尔通体中发现了一种抑制蛋白，可以显著降低人血管内皮细胞的生长，称为BIF。巴尔通体产生BAP和BIF表明该病原体在调节宿主细胞生长中起积极作用。然而，BAP和BIF的分子性质和机制尚不清楚。因此，本项目的长期目标是利用亨塞拉巴尔通体作为该属的模型来表征BIF及其作用机制。实现这些目标的具体目标将：1)利用生物化学和分子生物学技术在分子水平上表征BIF； 2)通过构建重叠的BAP缺失突变体并分析其抑制血管内皮细胞生长的能力，通过绘制其抑制活性所需的结构域来分析BIF的机制；3)在体外检测BIF和BAP的拮抗作用，并评估BIF在体内的血管抑制活性。4)通过鉴定和表征其同源内皮细胞受体，开展研究以阐明BIF的机制。这些实验将产生关于一种新型细菌蛋白的分子性质的有价值的数据，这种蛋白质可以调节人类血管内皮细胞的生长，并将有助于阐明在感染期间产生巴尔通体病血管瘤和假瘤性疾病表现的机制。